The development of therapies that specifically target known ALS mutations, including chromosome 9 open reading frame 72 (C9orf72) and superoxide dismutase 1 (SOD1), fused in sarcoma (FUS), has been rapidly evolving in recent years [6–8]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.